Hyperfine (HYPR) Cash from Financing Activities (2021 - 2026)
Hyperfine (HYPR) posted Cash from Financing Activities of $14.5 million for Q1 2026, down 24.87% on a QoQ basis from $19.3 million in Q4 2025, and up 159.51% year-over-year from $5.6 million in Q1 2025.
Hyperfine (HYPR) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Hyperfine's Cash from Financing Activities history runs 6 years deep, the most recent figure standing at $14.5 million for Q1 2026.
- Quarterly Cash from Financing Activities rose 159.51% year-over-year to $14.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.4 million (up 456.16% YoY) and the FY2025 annual result came in at $27.5 million, up 2598.92% from the prior year.
- Cash from Financing Activities was $14.5 million for Q1 2026 at Hyperfine, down from $19.3 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $19.3 million in Q4 2025 and bottomed at $5000.0 in Q4 2022.
- A 5-year average of $3.1 million and a median of $58500.0 in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities sank 100.0% — and 2025, when it jumped 35607.41%.
- Hyperfine's Cash from Financing Activities stood at $5000.0 in 2022, then jumped by 460.0% to $28000.0 in 2023, then jumped by 92.86% to $54000.0 in 2024, then soared by 35607.41% to $19.3 million in 2025, then fell by 24.87% to $14.5 million in 2026.
- Business Quant data shows HYPR's Cash from Financing Activities at $14.5 million in Q1 2026, $19.3 million in Q4 2025, and $2.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -25.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -26.93 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Hyperfine | 92.81 Mn | 51.53 Mn | 1.98 Mn | 14.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.49 Mn |
| Mar 31, 2026 | 14.49 Mn |
| Dec 31, 2025 | 19.28 Mn |
| Dec 31, 2025 | 19.28 Mn |
| Sep 30, 2025 | 2.16 Mn |
| Sep 30, 2025 | 2.16 Mn |
| Jun 30, 2025 | 474,000.00 |
| Jun 30, 2025 | 474,000.00 |
| Mar 31, 2025 | 5.58 Mn |
| Mar 31, 2025 | 5.58 Mn |
| Dec 31, 2024 | 54,000.00 |
| Dec 31, 2024 | 54,000.00 |
| Sep 30, 2024 | 851,000.00 |
| Sep 30, 2024 | 851,000.00 |
| Jun 30, 2024 | 59,000.00 |
| Jun 30, 2024 | 59,000.00 |
| Mar 31, 2024 | 55,000.00 |
| Mar 31, 2024 | 55,000.00 |
| Dec 31, 2023 | 28,000.00 |
| Dec 31, 2023 | 28,000.00 |